USCOM LIMITED — Regulatory Filings 2007

Nov 27, 2007

==> picture [80 x 96] intentionally omitted <==

MARKET ANNOUNCEMENT

New US patent for Uscom

Wednesday, 28 November 2007: Uscom (ASX Code: UCM) today announced the granting of its US patent no 10/761899, the method for determining cardiac valve dimensions based on body measurements and cardiac Doppler flow measurements. The granting of the US patent is recognition of the novelty and inventiveness of the method by the US Patent Office. The method allows non-invasive and accurate calculation of both left and right sided cardiac output making Uscom unique in the field of haemodynamic monitoring. This patent has applications beyond the Uscom device alone and could be used to simplify echocardiography, invasive catheter procedures and valve surgery. As well as commercial protection of the Uscom device, this granting may allow development of unique Uscom applications in the field of heart failure, hypertension and lung disease.

The patent author and Chairman of Uscom Ltd, Rob Phillips said “This is an important patent for us as it endorses our commercial ownership of the method at the core of the unique Uscom technology. Additionally the method extends beyond the Uscom device and has multiple other applications, potentially forming the foundation technology for new devices, or commercial opportunity associated with technology licensing or partnerships.”

Uscom CEO, Paul Butler, said “Intellectual property represents shareholder value and this is independent and rigorous recognition of the innovation within the Company. These patents reaffirm the intellectual strength of our company and will significantly contribute to the value of Uscom during strategic discussions. This takes Uscom’s patent portfolio to 32 separate patent cases directed to particular technologies, with 4 granted patents.”

Uscom is continuing to create an important global Medical Device Company on the back of unique IP covering a family of powerful cardiovascular measurement devices. Uscom is pursuing strategic alliances to advance global marketing, particularly in the USA, and furthering the adoption of Uscom technology through academic publications and the endorsement of Uscom guided management as a new standard of medical care.

www.uscom.com.au

Uscom Limited Level 7, 8-10 Loftus Street Sydney NSW 2000 Australia Phone: 61-2-9247 4144 Fax: 61-2-9247 8157 ABN: 35 091 028 090

About Uscom

Uscom Limited is an Australian medical device company, listed on the Australian Stock Exchange since December 2003. Uscom has developed a device for the safe and accurate measurement of cardiac output, a non-invasive alternative to the current invasive methods. Uscom offers a completely safe, painless and quick method of accurately measuring how well the heart is pumping. With its real-time beat-to-beat information across multiple parameters of cardiac function and advanced serial measurement capabilities, clinicians can accurately quantify the impact of therapy. The device is ideally suited to the Emergency Care setting where it is critical to monitor changes in cardiac output as fluids are applied.

The Company has secured regulatory approval for sale of the Uscom Monitor in Australia, Europe and a number of Asian markets, including Japan, China and Taiwan. Uscom also has a CE Mark certification for Europe and a license from the State Food & Drug Administration for China. The Company received the necessary regulatory clearance for the United States market in February 2005 with the receipt of a 510K Pre Market Notification from the US Food & Drug Administration (FDA).

Uscom Contacts

Paul Butler Chief Executive Officer Office: 02 9247 4144 paul.butler@uscom.com.au

Rob Phillips Executive Chairman Office: 02 9247 4144 rob@uscom.com.au

www.uscom.com.au

Uscom Limited Level 7, 8-10 Loftus Street Sydney NSW 2000 Australia Phone: 61-2-9247 4144 Fax: 61-2-9247 8157 ABN: 35 091 028 090